List view / Grid view
Monoclonal antibodies have shown great promise in the treatment of various cancers. This article discusses how therapeutic antibodies are produced and the various treatment strategies that are currently being adopted.
Researchers have discovered that B cells aid T cells in fighting cancer, which could be an area of development for immunotherapies.
A study has used a proteomic method to uncover why some melanoma tumours do not respond to immunotherapy, which could improve treatments.
Researchers have discovered the roles that immune cells play in tumour growth and breast cancer immunotherapy which could aid in drug development.
A new study from the University of Eastern Finland has shown that peripheral T helper cells may have a role in the development of type 1 diabetes.
The ISCT is objecting linking the benefits of cellular immunotherapy with third party offerings of T-cell banking for future therapeutics.
A novel nano-vaccine has been developed which has proven effective in treating primary tumours and metastases that result from melanoma.
New study shows the ability of CD8+ cytotoxic T cells to penetrate a large target, which opens avenues to destroy solid cancers.
Redundancies have been discovered in the biochemical signalling pathways of immune cells which could impact cancer immunotherapy.
This article outlines the exciting developments that are taking place with immunotherapies and demonstrates how stem-cell technologies are proliferating the paradigm shift in how we tackle cancer treatment.
Researchers have found that certain immune cells aid in fighting tuberculosis bacteria, providing a new drug target.
This in-depth focus looks at the modification of stem cells to facilitate their efficient delivery to tumours, highlighting the new development of pluripotent stem cells.
The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
Engineered T cell immunotherapy (such as chimeric antigen receptor T cell (CAR-T) and T cell receptor T cell (TCR-T) therapy), could potentially be used as a therapeutic strategy for tumour treatment.
